Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 3 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 3.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
3 of 7 appear on more than one
5 people on two or more of them
Christopher Staral is an independent director of JATT II Acquisition Corp. (NASDAQ: JATT), a Cayman Islands-incorporated special purpose acquisition company that priced its $60 million IPO in April 2026 and trades on Nasdaq under the symbol "JATT." The SPAC, led by Chairman and CEO Dr. Someit Sidhu and CFO Nicholas Fernandez, intends to combine with a healthcare or healthcare-related business with an emphasis on biotechnology and broader life sciences. Staral serves alongside fellow independent directors Verender S. Badial, Dr. Arjun Goyal, and Dr. Jonathon Kluft on the board, bringing extensive experience across biotechnology investing, company architecture, and the life sciences sector. He filed an initial statement of beneficial ownership of securities with the SEC in connection with his directorship in April 2026.
Beyond his SPAC role, Staral is the Founder, Managing Member, and Chief Investment Officer of an investment firm and the Founder and Managing Partner of Allostery Investments LP, based in the New York area. He appears in five SEC Form D filings as an Executive Officer and Promoter associated with two pooled investment fund entities: Allostery Fund LP and Allostery Offshore Fund Ltd., with filings spanning from September 2022 through December 2024. He also serves as a director at a second company identified in regulatory filings. Staral additionally helps lead healthcare investing at Laurion Capital Management, where he drives investment in both public and private healthcare companies, having joined the firm in 2020. Prior to Laurion, he was an Investment Analyst specializing in therapeutics at Mangrove Partners. Earlier in his career, Staral worked as a biopharma Equity Research Analyst at Goldman Sachs & Co. LLC in New York from September 2017 through January 2019, and before that as a biopharma Equity Research Associate at Canaccord Genuity. He has also served as a former Advisor at Rheos Medicines.
Staral's educational background includes a B.A. in Chemistry, magna cum laude, with a minor in Biochemistry from Carleton College. He subsequently attended the University of Minnesota Medical School before transitioning from medicine into finance. His BrokerCheck record (CRD# 6740328) identifies him as a previously registered broker with one year of experience and zero disclosures. His mailing address on SEC filings is listed in Westfield, New Jersey 07091, and he is also associated with Stamford, Connecticut in SEC Form D filings. Staral's career reflects a trajectory from medical training to sell-side biopharma equity research, then to buy-side therapeutics investing, and ultimately to founding his own investment vehicles while serving on the board of a life sciences-focused SPAC.
This record is keyed to SEC CIK 0002128365 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 9 institutional-holder rows on these vehicles, under 7 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.